FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA), also known as N-acetyl-L-aspartyl-L-glutamate peptidase 1 (NAALAD1) or glutamate carboxypeptidase 2, is an enzyme expressed by most prostate cancer cells and, in combination with different molecules such as gallium-68 or fluorine-18, is used as a radiopharmaceutical in PET/MRI and PET/CT [36,37].